Gainers
- Timber Pharmaceuticals TMBR shares increased by 87.9% to $2.8 during Monday's pre-market session. The company's market cap stands at $8.5 million.
- Evaxion Biotech EVAX shares moved upwards by 43.24% to $2.12. The market value of their outstanding shares is at $56.0 million. As per the press release, Q1 earnings came out 3 days ago.
- BiondVax Pharmaceuticals BVXV stock moved upwards by 27.64% to $2.17. The company's market cap stands at $7.1 million.
- CohBar CWBR stock rose 20.27% to $3.44. The market value of their outstanding shares is at $9.9 million.
- Amedisys AMED stock increased by 15.74% to $91.98. The company's market cap stands at $2.9 billion.
- Day One Biopharmaceutical DAWN shares increased by 14.7% to $15.6. The market value of their outstanding shares is at $1.1 billion.
Losers
- Bellerophon Therapeutics BLPH stock declined by 79.3% to $1.46 during Monday's pre-market session. The company's market cap stands at $15.2 million.
- Mallinckrodt MNK shares fell 23.08% to $1.88. The market value of their outstanding shares is at $24.8 million.
- Cibus CBUS shares fell 19.64% to $19.61. The company's market cap stands at $19.5 million.
- Castle Biosciences CSTL stock decreased by 16.42% to $19.0. The market value of their outstanding shares is at $507.1 million.
- Bluejay Diagnostics BJDX shares fell 13.73% to $0.21. The market value of their outstanding shares is at $4.3 million.
- Blueprint Medicines BPMC stock fell 9.76% to $52.54. The market value of their outstanding shares is at $3.1 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BJDXBluejay Diagnostics Inc
$3.63-%
BLPHBELLEROPHON THERPETCS INC by Bellerophon Therapeutics, Inc.
$0.0360200.0%
BPMCBlueprint Medicines Corp
$90.460.14%
CBUSCibus Inc
$2.69-5.28%
CSTLCastle Biosciences Inc
$27.720.87%
CWBRCohBar Inc
$0.610022.0%
DAWNDay One Biopharmaceuticals Inc
$12.67-0.16%
EVAXEvaxion Biotech AS
$0.91771.10%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in